Use of cangrelor in patients with reduced renal function: Post-hoc analysis from the ARCANGELO study. (PubMed, Int J Cardiol) - Jun 5, 2026 - "These data suggest that the transition from cangrelor to any oral P2Y12 inhibitor is a safe and effective treatment in patients with acute coronary syndrome and reduced renal function undergoing PCI in the setting of routine clinical practice."
Journal • Retrospective data • Acute Coronary Syndrome • Atrial Fibrillation • Cardiovascular • Coronary Artery Disease • Diabetes • Metabolic Disorders • Nephrology • Renal Disease
|
|
Carlo Cernetti; Carlo Di Mario; Carlo Trani; Ciro Mauro; Elisa Nicolini; Fabrizio Tomai; Francesco Versaci; Giuseppe Musumeci; Leonardo De Luca; Martino Pepe; Paolo Calabrò; Piera Capranzano; Plinio Cirillo; Sergio Berti
|